Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1

Interventions

Gemcitabine 6Irinotecan 5Oxaliplatin 4Magnetic Resonance Spectroscopy 4Surgical Procedures, Operative 3Specimen Handling 3Leucovorin 3Fluorouracil 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3palbociclib 2olaparib 2cobimetinib 2Radiosurgery 2Positron-Emission Tomography 2Oncolytic Virotherapy 2Nivolumab 2Ketamine 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Disulfides 2Cyclophosphamide 2Capecitabine 2Biopsy 2tremelimumab 1trastuzumab biosimilar HLX02 1toripalimab 1sonidegib 1pimonidazole 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pancreatic Neoplasms × paricalcitol × Clear all
NCT03519308 2024-03-15

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Terminated
3 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡